Abstract

Precision medicine represents a transformative approach to diabetes prevention and management, emphasizing 
individualized strategies based on genetic, genomic, epigenetic, environmental, and physiological factors. This 
narrative review synthesizes current literature on precision medicine applications in type 1 and type 2 diabetes, 
highlighting patient stratification, multi-omic integration, pharmacogenomics, biomarker-guided diagnostics, and 
the utilization of digital health and real-world data. Evidence indicates that tailoring therapeutic interventions 
according to patient-specific characteristics can improve glycemic control, optimize drug efficacy, and reduce 
adverse drug reactions. In type 1 diabetes, precision approaches facilitate early detection, beta-cell preservation, 
and individualized immunomodulatory strategies, whereas in type 2 diabetes, multidimensional analyses and 
pharmacogenomics enhance phenotypic classification and treatment personalization. Despite promising advances, 
barriers remain, including heterogeneity in disease phenotypes, limited access to comprehensive datasets, 
inequities in health technology adoption, ethical and privacy concerns, and insufficient clinical implementation of 
pharmacogenomic insights. Future research should prioritize longitudinal cohort studies, standardized 
methodologies, integration of high-dimensional multi-omic datasets, and equitable deployment of digital health 
solutions. By addressing these gaps, precision medicine has the potential to enhance individualized care, improve 
clinical outcomes, and transform the management of diabetes across diverse populations.